EASD 2024 New developments in presymptomatic type 1 diabetes screening
| ADAP Stock | USD 0.28 0.01 3.70% |
Slightly above 53% of Adaptimmune Therapeutics' retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Adaptimmune Therapeutics Plc suggests that some traders are interested. Adaptimmune Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Adaptimmune Therapeutics Plc. Many technical investors use Adaptimmune Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Adaptimmune | Build AI portfolio with Adaptimmune Stock |
This research addresses the early identification of type 1 diabetes, celiac disease, and autoimmune thyroid disease using innovative antibody detection technologies.
Read at finance.yahoo.com
 |
Adaptimmune Therapeutics Fundamental Analysis
We analyze Adaptimmune Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adaptimmune Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adaptimmune Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Adaptimmune Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Adaptimmune Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Adaptimmune Therapeutics stock to make a market-neutral strategy. Peer analysis of Adaptimmune Therapeutics could also be used in its relative valuation, which is a method of valuing Adaptimmune Therapeutics by comparing valuation metrics with similar companies.
Peers
Adaptimmune Therapeutics Related Equities
| AGIO | Agios Pharm | 0.71 | ||||
| PDSB | PDS Biotechnology | 0.64 | ||||
| CRVS | Corvus Pharmaceuticals | 0.58 | ||||
| NKTX | Nkarta | 1.13 | ||||
| STOK | Stoke Therapeutics | 1.47 | ||||
| MREO | Mereo BioPharma | 1.75 | ||||
| BDTX | Black Diamond | 2.43 | ||||
| LPTX | Leap Therapeutics | 2.70 | ||||
| PLRX | Pliant Therapeutics | 3.73 | ||||
| SGMO | Sangamo Therapeutics | 4.08 | ||||
| ACET | Adicet Bio | 4.17 | ||||
| INKT | Mink Therapeutics | 7.79 | ||||
| AFMD | Affimed NV | 18.18 |
Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.